Belgium· BE-AMP-SAM430586-00
Adcetris 50 mg
A brentuximab vedotin product containing brentuximab vedotine, registered in Belgium by Takeda Pharma. The same ATC class is registered in 13 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Brentuximab vedotin is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX05 (brentuximab vedotin), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Brentuximab vedotin · ATC L01FX05
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of brentuximab vedotin costs, country by country.
Normalised to the WHO defined daily dose (6 mg), the median price runs from $10.73 in Finland to $468.90 in Switzerland — a ×44 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Brentuximab vedotin · price per daily dose (6 mg)
USD · FX 28 Sept 2026
- CH Switzerland$468.90
- FI Finland$10.73
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Brentuximab Vedotine
- Manufacturer
- Takeda Pharma
- Country
- Belgium (BE)
- ATC code
- L01FX05
- ATC class
- Brentuximab vedotin
- Defined daily dose
- 6 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 4
- be_apb7708712
- be_apb3010774
- be_apb4219770
- be_apb7728561
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
535 interactions on record for brentuximab vedotin.
Graded by severity as the source publishes them — 33 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Brentuximab vedotin · interactions on record
535 records
- 33 severe
- 502 moderate
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- ClotrimazoleA01AB18moderate
- RolapitantA04AD14moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Brentuximab vedotin in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandADCETRISOrifarm Oy
- SpainADCETRIS 50 mg POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONTakeda Pharma A/S
- IrelandADCETRIS 50 mg powder for concentrate for solution for infusionTakeda Pharma A/S
- IcelandADCETRISTakeda Pharma A/S
- NorwayAdcetrisTakeda Pharma A/S (1)
- PolandAdcetrisTakeda Pharma A/S
- CzechiaADCETRISTakeda Pharma A/S, Vallensbaek Strand
- SwedenADCETRIS 50 mg Pulver till koncentrat till infusionsvätska, lösningTakeda Pharma A/S
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Adcetris
- Liechtenstein · Adcetris
- Norway · Adcetris
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/15bcfc6f-fb18-4a1b-b45d-3514a17b3faa GET /v1/drugs/15bcfc6f-fb18-4a1b-b45d-3514a17b3faa?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for concentrate for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Adcetris 50 mg",
"name_fr": "Adcetris 50 mg",
"name_nl": "Adcetris 50 mg",
"amp_code": "SAM430586-00",
"strengths": [
"50.0000"
],
"pack_count": 3,
"substances": [
"Brentuximab Vedotine",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Brentuximab Vedotin",
"authorisation_numbers": [
"EU/1/12/794/001"
]
}See everything about brentuximab vedotin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.